Abstract
Patients with diabetes have a risk of death that is two to six times that among persons without diabetes; the age-adjusted prevalence of coronary heart disease is twice as high among those with type 2 diabetes as among those without diabetes. The cardiovascular disease events associated with diabetes and the high incidence of other macrovascular complications, such as strokes, amputations, and myocardial infarction, are a major cause of morbidity and mortality, and an enormous economic burden.
Keywords
- Macrovascular Disease
- United Kingdom Prospective Diabetes Study
- Intensive Glycemic Control
- Intensive Glucose Control
- United Kingdom Prospective Diabetes Study Study
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. J Am Med Assoc. 1979;241:2035–8.
Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011;1:5–12.
Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest. 1994;70:138–51.
Bierhaus A, Hofmann MA, Ziegler R, et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998;37: 586–600.
Koya D, King GL. Protein kinase C activation and the development of diabetes complications. Diabetes. 1998;47:859–66.
Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447–56.
Egan BM, Lu G, Green EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids. 1999;60:411–1406.
Toft I, Bonna KH, Ingebresten OC, et al. Fibrinolytic function after dietary supplementation with omega 3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol. 1997;17:814–9.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). J Am Med Assoc. 2001;285(19):2486–97. NIH Publication No. 01–3670, May 2001.
Figler RA, Wang Q, Srinivasan S, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes. 2011;60(2):669–79.
Yamauchi T, Kamon J, Waki H, et al. Fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.
Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031–41.
Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocytes-derived plasma protein adiponectin. Circulation. 1999;100:2473–6.
O’Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc. 1998;73:969–76.
Schimdt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesion. Arterioscler Thromb. 1994;14:1521–8.
Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.
Szalai AJ, Van Ginkel FW, Wang Y, et al. Complement-dependent acute phase expression of C-reactive protein and serum amyloid P-component. J Immunol. 2000;165:1030–5.
Schneider DJ, Sobel BE. Diabetes and thrombosis. In: Johnstone MT, Veves A, editors. Diabetes and cardiovascular disease. Totowa, NJ: Humana Press; 2001. p. 107–28.
Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelium and nitric oxide activity in the human forearm. Circulation. 1999;100:820–5.
Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009–23.
Ren J, Pulakat L, Whaley-Connell A, et al. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med. 2010;88:993–1001.
Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384–7.
Whaley-Connell A, Pulakat L, DeMarco VG, et al. Overnutrition and the cardiorenal syndrome: use of a rodent model to examine mechanisms. Cardiorenal Med. 2011;1:23–30.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N EnglJMed. 1993;329:977–86.
Gaede P, Vedel P, Larsren N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–90.
Del Prato S. Megatrials in type 2 Diabetes. From excitement to frustration? Diabetologia. 2009;52:1219–26.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;369:129–40.
Heller SR, ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care. 2009;32 Suppl 2:S357–62.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
Dale AC, Vatten LJ, Nilsen TI, et al. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. Br Med J. 2008;337:99–102.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:580–91.
Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet. 2009;373:1765–72.
American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33:S11–48.
Acknowledgement
This work is supported by NIH R01-HL073101 and R01-HL107910 (JRS) and VA Merit Award (JRS).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Garcia-Touza, M., Sowers, J.R. (2012). Diabetes and Cardiovascular Disease. In: McFarlane, S., Bakris, G. (eds) Diabetes and Hypertension. Contemporary Diabetes. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-357-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-357-2_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-356-5
Online ISBN: 978-1-60327-357-2
eBook Packages: MedicineMedicine (R0)